Pregled bibliografske jedinice broj: 764195
Treatment of hyperuricemia with allopurinol in resistant hypertensive predialysis chronic kidney disease patients have additional positive effects on blood pressure and renal function
Treatment of hyperuricemia with allopurinol in resistant hypertensive predialysis chronic kidney disease patients have additional positive effects on blood pressure and renal function // Nephrology Dialysis Transplantation 2015 ; 30 (Suppl. 3): iii94-iii94
London, Ujedinjeno Kraljevstvo, 2015. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 764195 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Treatment of hyperuricemia with allopurinol in resistant hypertensive predialysis chronic kidney disease patients have additional positive effects on blood pressure and renal function
Autori
Prkačin, Ingrid ; Bulum, Tomislav ; Dražić, Petra ; Boras, Iva ; Vrhovec, Borna ; Legović, Ana
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Nephrology Dialysis Transplantation 2015 ; 30 (Suppl. 3): iii94-iii94
/ - , 2015
Skup
52nd ERA-EDTA Congress
Mjesto i datum
London, Ujedinjeno Kraljevstvo, 28.05.2015. - 31.05.2015
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
allopurinol; predialysis chronic kidney disease patients; resistant hypertension
Sažetak
Elevated levels of serum uric acid (SUA) have been associated with an increased risk of cardiovascular disease (CVD). Small studies have observed an antihypertensive effect of urate- lowering therapy with Allopurinol (A) in hyperuricemic patients and in obese adolescent males with hypertension. The aim of this study was to investigate effects of A therapy on blood pressure (BP) and renal function parameters in predialysis chronic kidney disease patients (CKDND) with resistant hypertension (RHp). A total of 50 RHp patients with CKDND were divided in two groups: 25 RHp who had BP readings taken before and after being prescribed A for 6 weeks (Group 1) and 25 RHp who had not taken A (Group 2. Treatment with A (Group 1) caused an additional significant reduction in clinic BP: systolic BP fell 9.8 mmHg, diastolic fell 8.0 mmHg, compared with Group 2. There was a reduction of BP that was not related to the primary uric acid level or to other drugs the patients were taking. The results of our study suggest that therapy with A in dose 200 mg daily lowered BP in RHp with CKDND without worsening of kidney function. Blocking the xanthine oxidase- mediated conversion of molecular oxygen to produce mediators of oxidative stres can partially explane additional BP lowering and safety of A in RHp with CKDND.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE